Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
Rezolute will present four abstracts at the Endocrine Society’s annual meeting, including an oral presentation on the Phase 3 sunRIZE study results. The sunRIZE study previously failed to meet its primary and key secondary efficacy endpoints in December 2025, though post-hoc analyses showed nominal glycemic improvements.
Key figures
- Drug Name
- ersodetug (RZ358)
- Phase Of Trial
- Phase 3
- Study name
- sunRIZE
- Study enrollment
- 63
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.